

**Attachments
To Witness Truth In Testimony Form
For
Dr. Ruud Dobber, Ph.D**

**Subcommittee on Oversight and Investigations
Committee on Energy and Commerce
U.S. House of Representatives**

**Pathway To Protection:
Expanding Availability of COVID-19 Vaccines
February 23, 2021**

ATTACHMENT 1

FEDERAL GRANTS OR CONTRACTS

1. Advanced Agreement, dated May 20, 2020, between the US Biomedical Advanced Research and Development Authority (BARDA) and AstraZeneca PLP, wherein the parties agreed to enter into a definitive agreement for procurement by BARDA of 300 million doses of the AZD1222 COVID-19 vaccine. Agreement value was \$413,200,000USD, representing 35% of the anticipated definitive award (approximately \$1.2 billion).
2. Other Transaction Authority Agreement, dated October 28, 2020 (undefinitized) and December 1, 2020 (definitized), between the Joint Program Executive Office (JPEO)/Department of Defense (DoD), wherein AZ agreed to clinically evaluate, scale-up manufacturing of, and deliver 100 million doses of AZD1222 COVID-19 vaccine. Agreement value is approximately \$1.2 billion USD.
3. Commercial Item (FAR Part 12) Agreement, dated October 28, 2020 (undefinitized) and December 1, 2020 (definitized), between the Joint Program Executive Office (JPEO)/Department of Defense (DoD), wherein AZ agreed to produce 25 batches of drug substance, and deliver 200 million doses of AZD1222 COVID-19 vaccine. Agreement value is approximately \$287 million USD.
4. Agreement, dated June 2, 2020, between BARDA, the US Defense Advanced Research Projects Agency (DARPA), and AstraZeneca, to support AstraZeneca's efforts to develop a monoclonal antibody treatment against COVID-19. Agreement value is estimated at \$25.1 million USD.
5. Other Transaction Authority Agreement, dated October 9, 2020 (undefinitized) and January 15, 2021 (definitized), between the Joint Program Executive Office (JPEO)/Department of Defense (DoD), wherein AZ agreed to clinically evaluate, scale-up manufacturing of, and deliver 100,000 doses of AZD7442 long-acting monoclonal antibody treatment. Agreement value is approximately \$476 million USD.
6. Commercial Item (FAR Part 12) Agreement, dated September 30, 2020 (undefinitized) and January 8, 2021 (definitized), between the Joint Program Executive Office (JPEO)/Department of Defense (DoD), wherein AZ agreed to deliver 100,000 300mg doses of AZD7442 long-acting monoclonal antibody treatment. Agreement value is approximately \$40 million USD.

ATTACHMENT 2

CONTRACTS OR PAYMENTS ORIGINATING WITH A FOREIGN GOVERNMENT

1. Since July 2020, AstraZeneca has entered into definitive agreements with numerous foreign governments to supply doses of AZD1222 COVID-19 vaccine, including agreements with the United Kingdom Government, the European Commission, the Government of Japan, the Australian Government, the Brazilian Government, the New Zealand Government, the Government of Thailand, the European Free Trade Association (consisting of Iceland, Liechtenstein, Norway, and Switzerland), the Government of Taiwan, the Government of Viet Nam, the Government of the Philippines, the Government of Brunei, the Malaysian Government, the Maldives Government, the Indonesian Government, the Government of Peru, and others.
2. AstraZeneca is currently in negotiations with additional countries; however, the final terms of these potential contracts are not available at this time.